skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients

Original Research

(2555) Views  (696) Full article downloads

Authors: Anand A Dalal, Meaghan St Charles, Hans V Petersen, et al

Published Date June 2010 Volume 2010:5 Pages 179 - 187
DOI: http://dx.doi.org/10.2147/COPD.S10988

Anand A Dalal1, Meaghan St Charles2, Hans V Petersen2, Melissa H Roberts2, Christopher M Blanchette2, Kathy Manavi-Zieverink3

1US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, 2Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Kannapolis USA; 3INC Research, Raleigh; NC, USA

Objective: To estimate the cost-effectiveness of fluticasone propionate–salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD).

Study design: Pooled economic analysis.

Methods: We performed an economic analysis of pooled data from two randomized clinical trials (combined N = 1554) that evaluated the effect of maintenance therapy with FSC (250/50 μg twice daily) or salmeterol (50 μg twice daily) on exacerbation rates in patients with severe COPD. We calculated exacerbation rates and applied standardized costs to exacerbation-related health care utilization reported in the trials (office, urgent care, and emergency department visits; hospitalizations; and oral corticosteroids and antibiotics) to determine cost differences between FSC and salmeterol treatment outcomes.

Results: Annual rates of any exacerbation and moderate/severe exacerbation were lower in the FSC group than the salmeterol group (4.91 vs 5.78 and 1.32 vs 2.00 respectively, both P < 0.05). Total adjusted annual COPD related exacerbation and therapeutic costs were $4,842 (95% CI; $4,731–$4,952) in the FSC group and $5,066 (95% CI; $4,937–$5,195) in the salmeterol group.

Conclusions: FSC combination therapy is associated with reduced risk of any exacerbation and moderate/severe exacerbation, and incurs lower annual COPD-related health care costs compared to treatment with salmeterol. This analysis demonstrates that FSC therapy may be advantageous from both a clinical and cost-benefit standpoint for patients with severe COPD.

Keywords: COPD, cost-effectiveness analysis, economic, maintenance therapy






 

Other articles by Dr Christopher Blanchette



Readers of this article also read:

Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction
Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
Clinical relevance of maximal inspiratory pressure: determination in COPD exacerbation
Modified BODE indexes: Agreement between multidimensional prognostic systems based on oxygen uptake
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies
An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
Changes in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy subjects
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
  • Journal Indexing

    See where all the Dove Press journals are indexed

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio